Imperial Oil Limited Common Stock vs Organon & Co. Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Imperial Oil Limited Common Stock is far larger — about 17.2× Organon & Co. Common Stock's market cap, and Imperial Oil Limited Common Stock pays the higher dividend (1.9%). Which is the better fit depends on your goals.
| IMO | OGN | |
|---|---|---|
Market Cap | $62.22B | $3.62B |
Volume | 560,544 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $138.33 | $13.81 |
52-Week Low | $83.72 | $5.70 |
Enterprise Value | $63.13B | $11.04B |
Dividend Yield | 1.9% | 0.58% |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →